A Successful Elimination of Indonesian SARS-CoV-2 Variants and Airborne Transmission Prevention by Cold Plasma in Fighting COVID-19 Pandemic: A Preliminary Study

Nur, Muhammad; Nidom, Chairul A.; Indrasari, Setyarina; Ansori, Arif Nur Muhammad; Alamudi, M. Yusuf; Nidom, Astria N; Sumariyah, Sumariyah; Sasmita, E.; Yulianto, Edy; Kinandana, Andi W.; Usman, Anwar; Kusala, Muhammad K. J.; Normalina, Irine; Nidom, Reviany V.

doi:10.33640/2405-609x.3234

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study we used two Indonesian SARS-CoV-2 isolates that have been deposited in the GISAID database (hCoV-19/Indonesia/JI-PNF-217315/2021 -EPI_ISL_12777089 or lineage B.1.617.2 and hCoV-19/Indonesia/JI-PNF-211373/2021 -EPI_ ISL_6425649 or lineage B.1.470) 6 .…”

Section: Virus Isolatesmentioning

confidence: 99%

See 1 more Smart Citation

Curcumin from Curcuma longa L. as Dual Inhibitors Against Indonesian SARS-CoV-2 Isolates: A Molecular Docking Study

Nidom¹,

Ansori²,

Nidom³

et al. 2023

Pharmacogn J.

View full text Add to dashboard Cite

Using Lipinski's rule of five on the SCFBIO web server (http://www.scfbio-iitd. res.in/software/ drugdesign/lipinski.jsp), curcumin was utilized for further drug-likeness analysis. It was regarded as a successful forecast when two minimal guidelines ABSTRACT COVID-19 has become a global pandemic since 2020. The search for promising drugs based on the abundant herbal ingredients in Indonesia is one of the breakthroughs. Curcumin is a chemical compound with various potentials such as antioxidant, anti-inflammatory and antiviral. We conducted a molecular docking analysis to determine the potential of curcumin against SARS-CoV-2 non-structural and structural proteins, such as the main protease and spike protein. This study used the compound of curcumin (PubChem CID: 969516) from Curcuma longa L. or turmeric and two Indonesian SARS-CoV-2 isolates that have been deposited in the GISAID database (hCoV-19/Indonesia/JI-PNF-217315/2021 -EPI_ ISL_12777089 or lineage B.1.617.2 and hCoV-19/Indonesia/JI-PNF-211373/2021 -EPI_ISL_6425649 or lineage B.1.470). In addition, we used molnupiravir (PubChem CID: 145996610) as a drug control. We performed molecular docking analysis with PyRx software 0.9.9 (academic license) and visualization of molecular docking results with PyMOL software 2.5.4 (academic license). The results of this study found that curcumin had good potential against main protease and spike protein compared to the drug (control). In summary, we suggested that curcumin is a potential drug candidate against SARS-CoV-2. However, there is a need for future wet laboratory-based pre-clinical research such as in vitro and in vivo.

show abstract

Section: Virus Isolatesmentioning

confidence: 99%

“…Older people and people with underlying medical conditions, such as cancer, diabetes, cardiovascular disease, or chronic respiratory disorders, are more prone to have severe illness. Anyone can get COVID-19 and become seriously ill or die at any age [1][2][3][4][5][6][7] .…”

Section: Introductionmentioning

confidence: 99%

Curcumin from Curcuma longa L. as Dual Inhibitors Against Indonesian SARS-CoV-2 Isolates: A Molecular Docking Study

Nidom¹,

Ansori²,

Nidom³

et al. 2023

Pharmacogn J.

View full text Add to dashboard Cite

show abstract

“…other provinces in China, Thailand, Japan, and South Korea. At first this disease was referred to as 2019-novel coronavirus (2019-nCoV), then on February 11, 2020 World Health Organization announced a new name, namely COVID-19 (Afiahayati et al, 2022;Ansori et al, 2020;Ansori et al, 2021;Nur et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Protection and profile of immune response against SARS-CoV-2 among the COVID-19 vaccinated and unvaccinated individuals

Nidom

Madyawati

Rachmawati

et al. 2022

ijhs

Self Cite

View full text Add to dashboard Cite

Coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first reported in the city of Wuhan, China at the end of December 2019. In the case of SARS-CoV-2, antibody-mediated immunity and T cells are the most effective protection. This study aimed to analyze IFN-γ profile in people who were vaccinated and unvaccinated against COVID-19. This research was conducted at the Molecular Laboratory of the Professor Nidom Foundation (LM-PNF), Surabaya, Indonesia from February 2021 to March 2022 using 100 blood samples with details of 50 samples from people who had been vaccinated against COVID-19 and 50 samples from people who had unvaccinated against COVID-19. We divided into four: vaccination only, vaccination and had infected of COVID-19 or survivors, unvaccination only, and unvaccination but survivors. Furthermore, we used the ELISpot method to see the IFN-γ profile. The data analysed by using ANOVA. The results of this study showed that IFN-γ profile vary widely with the highest IFN-γ obtained in samples of people who are vaccinated and had infected of COVID-19 compared to other groups. In summary, we conclude that the cellular immune response (IFN-γ) profile in people who vaccinated and had infected of COVID-19 was better than unvaccinated.

show abstract

Diagnostic Values of SARS-COV-2 Antibodies using Lifotronic ECL-8000

Kartika Syamsuddin,

Wardhani,

Aryati

2023

RJPT

View full text Add to dashboard Cite

One of the most definitive diagnostic tests for COVID-19 infection is rRT-PCR. Another modality developed to diagnose COVID-19 infection is the antibody (serological) assay. This essay can be performed quickly and easily but requires high sensitivity and specificity. This study aims to analyze the diagnostic values of anti-SARS-CoV-2 IgM and IgG using Lifotronic ECL-8000 and the development of antibodies based on time after the onset of the symptoms of COVID-19 in patients with confirmed COVID-19 infection. The serum of the patients with confirmed COVID-19 infection by rRT-PCR was collected between day 1 and day 21 after the onset of the symptoms. Anti-SARS-CoV-2 IgM and IgG from each sample were measured using Lifotronic ECL-8000 to determine their sensitivity, specificity, PPV, and NPV. This assay detects IgM against SARS-CoV-2 N and SRBD proteins, as well as IgG against SARS-CoV-2 SRBD proteins. The anti-SARS-CoV-2 IgM serological assays using Lifotronic ECL-8000 indicated that IgM had 91.6% sensitivity, 87.03% specificity, 90.4% PPV, and 88.67% NPV. Meanwhile, the anti-SARS-CoV-2 IgG serological assays using Lifotronic ECL-8000 showed that IgG had 93.05% sensitivity, 88.88% specificity, 91.78% PPV, and 90.56% NPV. The development of antibodies was observed on days 0-7 after the onset of the symptoms, and the positivity rate of anti-SARS-CoV-2 IgM was higher than that of anti-SARS-CoV-2 IgG. Starting from day 8 after the onset of the symptoms, the positivity rate of anti-SARS-CoV-2 IgG increased and remained higher than that of anti-SARS-CoV-2 IgM. It was concluded that anti-SARS-CoV-2 IgM and IgG serological assays using Lifotronic ECL-8000 could be utilized to support the diagnosis of patients with suspected COVID-19 infection with high sensitivity and specificity.

show abstract

A Successful Elimination of Indonesian SARS-CoV-2 Variants and Airborne Transmission Prevention by Cold Plasma in Fighting COVID-19 Pandemic: A Preliminary Study

Cited by 3 publications

References 0 publications

Curcumin from Curcuma longa L. as Dual Inhibitors Against Indonesian SARS-CoV-2 Isolates: A Molecular Docking Study

Curcumin from Curcuma longa L. as Dual Inhibitors Against Indonesian SARS-CoV-2 Isolates: A Molecular Docking Study

Protection and profile of immune response against SARS-CoV-2 among the COVID-19 vaccinated and unvaccinated individuals

Diagnostic Values of SARS-COV-2 Antibodies using Lifotronic ECL-8000

Contact Info

Product

Resources

About